Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label Lamazym study in alpha-mannosidosis patients previously treated in Lamazym trials
2014-003950-15Phase 3Completed
- Sponsor
- Zymenex
- Start
- Nov 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of velmanase alfa in alpha-mannosidosis, sponsored by Zymenex. Primary endpoint: Serum oligosaccharides. Started Nov 2014; status: completed.
02
Drugs
velmanase alfa
03
Conditions
alpha-mannosidosis
Beyond the preview
Go deeper on 2014-003950-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003950-15.